Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Italian Pricing Decree To Drive R&D Transparency

Companies Are Concerned That Revealing R&D Funding will Reduce Prices

Executive Summary

Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.

You may also be interested in...



Italy To Consult On Pricing Transparency Requirements

Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.

WTO Price Transparency Talks Face Resistance From Developed Countries

Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.

Italy: Added Benefit Will Be Key To Reimbursement

A draft decree in Italy aims to put added therapeutic value at the centre of reimbursement decisions.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel